Processa Pharmaceuticals (PCSA) Non Operating Interest Expenses (2012 - 2021)

Processa Pharmaceuticals (PCSA) has reported Non Operating Interest Expenses for 10 consecutive years, with $362.0 the latest figure, recorded in Q1 2021.

• For the quarter ending Q1 2021, Non Operating Interest Expenses fell 97.89% year-over-year to $362.0; the trailing twelve-month figure through Dec 2021 stood at $362.0 (down 99.91% YoY), and the FY2021 full-year result was $362.0, down 99.87% from the prior year.
• Non Operating Interest Expenses retreated to $362.0 in Q1 2021 per PCSA's latest filing, from $197403.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $197403.0 in Q4 2020 and bottomed at -$110450.0 in Q4 2017.
• Historically, Non Operating Interest Expenses has averaged $39844.1 across 5 years, with a median of $19280.0 in 2020.
• The sharpest annual moves came in 2017 and 2020: Non Operating Interest Expenses sank 274.43% in 2017, then soared 8099.43% in 2020.
• Over 5 years, Non Operating Interest Expenses stood at -$110450.0 in 2017, then soared by 106.18% to $6828.0 in 2018, then jumped by 246.88% to $23685.0 in 2019, then surged by 733.45% to $197403.0 in 2020, then plunged by 99.82% to $362.0 in 2021.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $362.0, $197403.0, and $186209.0 for Q1 2021, Q4 2020, and Q3 2020 respectively.